Pavmed Inc. · NASDAQ:PAVM
Pavmed — Q3 2025 Earnings Presentation
11 slides from Pavmed's earnings presentation, Nov 13, 2025
Slide 1: Q3 2025 Business Update
Nasdaq: PAVM Q3 2025 Business Update November 13, 2025 LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements
Slide 3: Lishan Aklog, M.D. Chairman & CEO
Nasdaq: PAVM Lishan Aklog, M.D. Chairman & CEO
Slide 4: Recent Highlights: Lucid Diagnostics
Recent Highlights Lucid Diagnostics ▪3Q25 EsoGuard revenue $1.2M; 3Q25 test volume 2,841 ▪MolDX Contractor Advisory Committee (CAC) Meeting held September 4; panel of clinical experts unanimously endorsed Medicare coverage for EsoGuard ▪Strengthened balance sheet with underwritten public offering of
Slide 5: Recent Highlights: Veris Health
Recent Highlights Veris Health ▪ Launched Commercial Phase of Strategic Partnership with OSU ▪ Relaunched implantable physiological monitor development ahead of planned 2026 FDA 510(k) submission ▪ Focused on executing expanded vision for Veris ▪ Commercial expansion ▪ Value add offerings beyond rem
Slide 6: Q3 2025 Financial Update
Nasdaq: PAVM Q3 2025 Financial Update
Slide 7: Balance Sheet
Balance Sheet ($ in thousands) 3Q25 2Q25 Change Assets Cash $3,103 $4,004 $(901) Equity Method Investments (Lucid) $31,615 $35,998 $(4,383) All other Assets $3,351 $3,891 $(540) Liabilities Accounts Payable $342 $387 $(45) Senior Secured Convertible Notes $6,900 $6,800 $100 Other Current Liabilities
Slide 8: P&L 3Q25 3Q24
P&L ($ in thousands) 3Q25 3Q24 Change 3Q25 - YTD 3Q24 - YTD Change Revenue + Management Fee Income $3,155 $4,146 $(991) $9,469 $11,135 $(1,666) Operating Expenses $4,849 $12,574 $(7,725) $15,022 $42,285 $(27,263) Net Income (Loss) $(6,011) $60,711 $(66,722) $288 $27,285 $(26,997) EBITDA $(5,363) $64
Slide 9: Non-GAAP Operating Expense
Non-GAAP Operating Expense To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. Non-GAAP financial measures are presented with the i
Slide 10: Q&A
XK PAVmed Nasdaq: PAVM aty Q&A
Slide 11: Closing Remarks
Nasdaq: PAVM Closing Remarks